Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SQLE | Q14534 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766489 | 0.87 | SMN1; SMN2 (0.36) | METAP1CXCR4S1PR4S1PR1S1PR3 | |
| SCHEMBL22054640 | 0.80 | SMN1; SMN2 (0.45) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL20792784 | 0.80 | SMN1; SMN2 (0.45) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL24107359 | 0.76 | EPHX1 (0.41) | SMN1; SMN2 | |
| SCHEMBL14805674 | 0.76 | ALB (0.35) | SMN1; SMN2SIRT5 | |
| SCHEMBL24220957 | 0.74 | SMN1; SMN2 (0.41) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL4621858 | 0.74 | FOLH1 (0.41) | — | |
| SCHEMBL13839054 | 0.73 | TLR2 (0.40) | — | |
| SCHEMBL23094931 | 0.73 | CHRNB2 (0.44) | SMN1; SMN2 | |
| SCHEMBL27267584 | 0.73 | CHRNB2 (0.42) | METAP1S1PR4S1PR1S1PR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | METAP1 488/4885CXCR4 239/4885S1PR4 1019/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | METAP1 488/4885CXCR4 239/4885S1PR4 1019/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | METAP1 740/4885CXCR4 404/4885S1PR4 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.